eli lilly lawsuit tirzepatide Mounjaro - July 2026 Update FDA says the tirzepatide weight-loss

There are no formulary restrictions, no rebate negotiations, no specialty tier

Prescribers longstanding preferences for established injectables, along with the commonly held view that injections are more effective, can also shape adoption

Treatment typically starts at 2.5 mg once weekly for 4 weeks, allowing patients to acclimate to the medication while minimizing potential side effects

Users also experienced a substantial reduction in knee pain

This medication has shown significant weight loss results, with patients losing up to 15-17% of their body weight in clinical trials

The SURMOUNT-3 trial demonstrated this clearly